Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000811 · ClinicalTrials.gov registry record · Phase 2
A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 690
- Enrollment target
NCT00000811 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 690 participants.
The verdict
NCT00000811, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 690 participants
- Enrollment target
Study Summary
This study compares 2 different treatments administered to try to prevent serious bacterial infections (such as pneumonia) in HIV-positive children. A combination of drugs (azithromycin plus atovaquone) will be compared to sulfamethoxazole-trimethoprim (SMX/TMP) alone. This study also evaluates the long-term safety and tolerance of these different drugs. SMX/TMP is a commonly prescribed drug for the prevention of bacterial infections. However, the combination of azithromycin and atovaquone may be safer and more effective than SMX/TMP. This study compares the 2 treatments.
Interventions
- DRUG Azithromycin
- DRUG Atovaquone
- DRUG Sulfamethoxazole-Trimethoprim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 690 participants |
| Est. Completion | 2001-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000811
The ClinicalTrials.gov registry entry for NCT00000811 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 690 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Azithromycin is the first listed.
NCT00000811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000811 about?
NCT00000811 is a clinical study titled "A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children". This study compares 2 different treatments administered to try to prevent serious bacterial infections (such as pneumonia) in HIV-positive children. A combination of drugs (azithromycin plus atovaquone) will be compared to sulfamethoxazole-trimethoprim (SMX/TMP) alone. This study also evaluates the ...
What is the current status of trial NCT00000811?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 690 participants. Estimated completion is 2001-11.
What interventions are being tested in trial NCT00000811?
The interventions under investigation include: Azithromycin (DRUG), Atovaquone (DRUG), Sulfamethoxazole-Trimethoprim (DRUG).
Who is sponsoring clinical trial NCT00000811?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.